The molecular mechanism revealed that CIS can directly target JAK1, a downstream protein of IL-15, by inhibiting the kinase activity of JAK and reducing the JAK protein level through ubiquitination and proteasomal degradation. The gene discussed is IL15; the disease is in situ carcinoma.